

January 11, 2022

To
The BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001.

Sub: Outcome of Board Meeting held on January 11, 2022
Scrp Code: 542724

Dear Sir/Madam,

We are to inform you that a Meeting of Board of Directors of the Company was convened today i.e. January 11, 2022 (Commenced at 12:00 P.M. and Concluded at: 01:05 P.M.), wherein the Unaudited Financial Results (IND AS) for the quarter and nine months ended December 31, 2021 were considered and approved.

Accordingly, we are sending herewith copy of Unaudited Financial Results (IND AS) along with copy of Limited Review Report given by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2021.

Kindly take the same on your records.

Thanking You.

Yours Faithfully,
For, EARUM PHARMACEUTICALS LIMITED



PRIYA RAVAL
COMPANY SECRETARY &
COMPLIANCE OFFICER

EARUM PHARMCEUTICALS LIMITED

CIN: L24230GJ2012PLC071299

Registered Office: "G-1, V R COMPLEX, Nr.SANATHAL CROSS ROAD, S P RING ROAD, SANATHAL, AHMEDABAD-382210"

Phone: +91 79 48402525, E mail: cs@earumpharma.com, Website: www.earumpharma.com

Statement of Unaudited Financial Results For The Quarter and Nine Months Ended on 31.12.2021

All amount in Rs. Lacs unless otherwise stated

Sr. No.	Particulars	3 months Ended	3 months Ended	Corresponding	9 Months ended	Corresponding 9	Year Ended
		31.12.2021	30.09.2021	3 months Ended	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	31.12.2020	(Unaudited)	(Unaudited)	(Audited)
				(Unaudited)			
1	Revenue from operations						
	(a) Net sales/income from operations (Net of excise duty)	488.69	842.29	277.14	1,629.73	4,162.23	4,108.37
	(b) Other Income	-	220.04	332.82	228.26	640.45	893.20
	Total Revenue	488.69	1,062.33	609.96	1,857.99	4,802.68	5,001.57
2	Expenses						
	(a) Cost of materials consumed			-	-	-	-
	(b) Purchase of Stock in Trade	480.39	388.29	652.05	1,173.11	4,194.80	4,834.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(91.28)	98.18	(46.06)	334.94	478.98	(206.94)
	(d) Employee benefits expense	-	0.66	7.32	2.15	23.20	29.30
	(e) Finance Cost	-	0.96	22.62	8.22	68.28	93.05
	(f) Depreciation and amortisation expense	3.55	4.97	-	11.68	5.97	12.30
	(g) Other expenses	0.69	29.30	7.25	33.89	216.61	227.94
	(i) Power Expenses			-	-	-	-
	(j) Fuel Expenses			-	-	-	-
	Total expenses	393.35	522.36	643.18	1,563.99	4,987.84	4,989.81
3	Profit/(Loss) from operations before an Exceptional and Extra ordinary items and Tax (1-2)	95.34	539.97	(33.22)	294.00	(185.16)	11.76
4	Exceptional Items			-	-	-	-
5	Profit/(Loss) from ordinary activities before an Extra Ordinary items and Tax (3 - 4)	95.34	539.97	(33.22)	294.00	(185.16)	11.76
6	Extra Ordinary Items			-	-	-	-
7	Profit/(Loss) from ordinary activities before tax (5 - 6)	95.34	539.97	(33.22)	294.00	(185.16)	11.76
8	Tax Expense (net)						
	- Current tax			-	-	-	2.94
	- Deffered tax			-	-	-	-
	Total Tax Expenses			-	-	-	2.94
9	Net Profit(Loss) for the Period from continuing operations	95.34	539.97	(33.22)	294.00	(185.16)	8.82
10	Profit(Loss) From Discontinuing operations before tax			-	-	-	-
11	Tax Expense of discontinuing Oprations			-	-	-	-
12	Net Profit(loss) from discontinuing Oprations after Tax			-	-	-	-
13	Profit(loss) for period before minority interest	95.34	539.97	(33.22)	294.00	(185.16)	8.82
14	Share of profits(loss) of subsidiary			-	-	-	0.29
15	Profit(loss) of minority Interest			-	-	-	-
16	Net Profit(loss) for the period	95.34	539.97	(33.22)	294.00	(185.16)	8.82
17	Details of Equity share capital						
	(a) Paid up Equity Share capital	1,233.58	1,233.58	616.79	1,233.58	616.79	616.79
	(b) face value of Equity share capital(in Rs.)	2.00	10.00	10.00	2.00	10.00	10.00
	(c)Other Equity Exculding Revaluation Reserve	510.55	415.21	648.17	510.55	648.17	833.33
18	Earnings per share (before extra ordinary items) (of Rs. 2 each) (not annualised):						
	(a) Basic	0.15	4.38	-0.54	0.48	-3.00	0.14
	(b) Diluted	0.15	4.38	-0.54	0.48	-3.00	0.14
19	Earnings per share (after extra ordinary items) (of Rs. 2 each) (not annualised):						
	(a) Basic	0.15	4.38	-0.54	0.48	-3.00	0.14
	(b) Diluted	0.15	4.38	-0.54	0.48	-3.00	0.14

For, EARUM PHARMACEUTICALS LIMITED

BHUMISHTH PATEL
MANAGING DIRECTOR
DIN : 02516641

DATE : 11.01.2022
PLACE : AHMEDABAD

Ref. No. :

Date :

LIMITED REVIEW REPORT

Auditor's Report on Quarterly and ^{Nine month ended} Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Earum Pharmaceuticals Limited


1. We have reviewed the accompanying statement of standalone unaudited financial results ("the statement") of Earum Pharmaceuticals Limited ("the Company") for the quarter ended 31st December, 2021, and year to date from 1st April 2021 to 31st December, 2021 being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard -34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India read with the Listing Regulations.. Our responsibility is to issue a report on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. We also performed procedure in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in the terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement except GST Proceeding.

Place: Ahmedabad
Date: 11/01/2022

For, M/s J M Patel & Bros.,
CHARTERED ACCOUNTANTS
FRN.: 107707W



Jashwant M Patel
CA JASHWANT M PATEL
(PROPRIETOR)
M. NO.: 030161
UDIN: 22030161AAAABS3335

Notes:

1. The financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors of the Company at their respective meetings held on January 11, 2022.
2. During the period under review, the Company has done Split of Shares as on December 18, 2021 i.e. record date, in the ratio of 1:5 i.e. Existing One (1) equity share of face value of Rs. 10/- each to be split into five (5) equity shares of face value Re.2/- each.
3. The Statutory Auditors of the company have carried out the limited review in respect of the financial results for the quarter ended December 31, 2021.
4. There are no separate reportable segments as per IND-AS 108 on "Operating Segments" in respect of the Company.
5. The figures for the previous quarter/ year have been regrouped/reclassified wherever necessary to make them comparable.
6. In preparation of Financial Results for the quarter and nine months ended December 31,2021, the Company has taken into account the possible impact of COVID-19 and the related internal and external factors known to the management upto the date of approval of these results
7. The results for the quarter ended December 31, 2021 are available on the website of BSE Limited i.e. www.bseindia.com and on the Company's website i.e. www.eaumpharma.com.

For EARUM PHARMACEUTICALS LIMITED

DATE: JANUARY 11,2022
PLACE: AHMEDABAD

BHUMISHTH N.PATEL
MANAGING DIRECTOR
[DIN: 02516641]